[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU6220398A - Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity - Google Patents

Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Info

Publication number
AU6220398A
AU6220398A AU62203/98A AU6220398A AU6220398A AU 6220398 A AU6220398 A AU 6220398A AU 62203/98 A AU62203/98 A AU 62203/98A AU 6220398 A AU6220398 A AU 6220398A AU 6220398 A AU6220398 A AU 6220398A
Authority
AU
Australia
Prior art keywords
scarring
receptor
mediated activity
inhibiting interleukin
reducing fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62203/98A
Inventor
Mark William James Ferguson
Sharon O'kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Publication of AU6220398A publication Critical patent/AU6220398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU62203/98A 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity Abandoned AU6220398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9702944.1A GB9702944D0 (en) 1997-02-13 1997-02-13 Reducing fibrosis
GB9702944 1997-02-13
PCT/GB1998/000319 WO1998036061A2 (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Publications (1)

Publication Number Publication Date
AU6220398A true AU6220398A (en) 1998-09-08

Family

ID=10807559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62203/98A Abandoned AU6220398A (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Country Status (3)

Country Link
AU (1) AU6220398A (en)
GB (1) GB9702944D0 (en)
WO (1) WO1998036061A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
WO2000029581A1 (en) 1998-11-13 2000-05-25 Immunex Corporation Human tslp dna and polypeptides
RU2292394C2 (en) * 2000-06-30 2007-01-27 ЗАЙМОДЖЕНЕТИКС, Инк., Interferon-like protein zcyto21
WO2003032898A2 (en) 2001-07-23 2003-04-24 Immunex Corporation Modified human thymic stromal lymphopoietin
EP1572103A4 (en) * 2002-11-15 2008-02-13 Centocor Inc Anti-angiogenic uses of il-6 antagonists
JP4960096B2 (en) * 2003-09-22 2012-06-27 ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of compounds that reduce the biological effects of IL-6
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
BRPI0617378B8 (en) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd USE OF AN IL-6 INHIBITOR TO PRODUCE A PHARMACEUTICAL COMPOSITION TO SUPPRESS DAMAGE TO AN ISLE TRANSPLANTATION AFTER ISLE TRANSPLANTATION; AND IMPROVE THE FEASIBILITY OF AN ISLAND IN AN ISLAND TRANSPLANTATION
AR058135A1 (en) * 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd AGENTS FOR THE TREATMENT OF CARDIOPATIAS
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (en) 2006-04-07 2015-07-29 国立大学法人大阪大学 Muscle regeneration promoter
CA2657763C (en) 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof
WO2008090901A1 (en) 2007-01-23 2008-07-31 Shinshu University Chronic rejection inhibitor
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP5544290B2 (en) 2008-06-05 2014-07-09 独立行政法人国立がん研究センター Nerve infiltration inhibitor
RS63800B1 (en) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Antitumor t cell response enhancer
JP2015506363A (en) 2012-01-13 2015-03-02 プレジデント アンド フェローズ オブ ハーバード カレッジ Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
WO2018109174A2 (en) 2016-12-16 2018-06-21 Singapore Health Services Pte Ltd Il-11 antibodies
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11344603B2 (en) * 2017-07-19 2022-05-31 Auckland Uniservices Limited Cytokine modulation
EP3698808A4 (en) 2017-10-20 2021-07-14 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
WO2020152122A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
KR20240067079A (en) 2021-08-30 2024-05-16 라센 테라퓨틱스 1, 인코포레이티드 Anti-IL-11Rα antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
JP3525221B2 (en) * 1993-02-17 2004-05-10 味の素株式会社 Immunosuppressants
WO1994025036A1 (en) * 1993-04-30 1994-11-10 Chugai Seiyaku Kabushiki Kaisha Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor
PL182089B1 (en) * 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
IT1274782B (en) * 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130
AU3193097A (en) * 1996-06-20 1998-01-07 Koster, Henk W. Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity

Also Published As

Publication number Publication date
GB9702944D0 (en) 1997-04-02
WO1998036061A3 (en) 1998-11-12
WO1998036061A2 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
AU6220398A (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
AU6244098A (en) Distributed game
AU3741699A (en) Personal location system
AU4943200A (en) Modified cytokine
AU4723296A (en) Compositions having depigmenting activity, and uses thereof
AU3206697A (en) Ribozyme-mediated gene replacement
AU6508198A (en) Ink additives
AU1024899A (en) Cytokines having neurotrophic activity
AU2321397A (en) Construction block structure
AU5203698A (en) Fluid-treatment assemblies
EP0903415A3 (en) Structure expansée
AU8165298A (en) Cardiotrophin-like cytokine
AU7474998A (en) Haloisoquinoline carboxamide
AU7020398A (en) Personal communications system
AU9367198A (en) Enzymatic modification
AU1365499A (en) Pre-orienting nozzle
AU3702399A (en) Catalytically active structure
AU6230398A (en) Thrombolytic agent
AU1873499A (en) Semi-submersible structure
AU8736698A (en) Shale-stabilizing additives
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
AU7162898A (en) Regioisomeric benzothiopyranopyridines having antitumor activity
AU8808098A (en) Bis-acridinecarboxamides having antitumor activity
AU7226598A (en) Stay
AU4414699A (en) Printhead attachment structure and method